Quatrefolic® receives EFSA positive scientific opinion

October, 3rd 2013

The European Food Safety Authority (EFSA) has adopted a positive scientific opinion on the safety and efficacy of Quatrefolic® opening the way for the commercialization of the novel ingredient in Europe in the next months...

 

Gnosis wins the NBT Awards 2013 for Mythocondro®, as the “Most effective product development strategy”

May, 16th 2013

Gnosis excels at the Nutraceutical Business & Technology (NBT) Awards with Mythocondro®, the first non-animal chondroitin sulfate (CS), winning the price in one of the most prestigious category, “The most effective product development strategy”...

 

Mythocondro® the first non-animal chondroitin sulfate, reaches the arena of finalists at the NBT Awards 2013

April, 10th 2013

Gnosis’ Mythocondro®, the first non-animal chondroitin sulfate (CS), has been selected as one of the finalists for the Nutraceutical Business & Technology (NBT) Awards, in three different categories such as the “Most Effective Product Development Strategy”, the “Outstanding Application in Health Management and the “Best New Product”....

 

< Turn back

 

 

 

 

GNOSIS S.P.A. Sede Legale: Piazza del Carmine, 4 20121 Milano. P. IVA 02484720129 C. F. 10197170151 Cap. Soc. 3.000.000,00 € i.v. Registro delle imprese di Milano N° 10197170151